Objective: To investigate the association of combined serum neurofilament light chain (sNfL) and retinal optical coherence tomography (OCT) measurements with future disease activity in patients with early multiple sclerosis (MS).
Methods: We analyzed sNfL by single molecule array technology and performed OCT measurements in a prospective cohort of 78 patients with clinically isolated syndrome and early relapsing-remitting MS with a median (interquartile range) follow-up of 23.9 (23.3-24.7) months. Patients were grouped into those with abnormal or normal sNfL levels, defined as sNfL ≥/<80th percentile of age-corrected reference values. Likewise, patients were grouped by a median split into those with thin or thick ganglion cell and inner plexiform layer (GCIP), peripapillary retinal nerve fiber layer, and inner nuclear layer in nonoptic neuritis eyes. Outcome parameters were violation of no evidence of disease activity (NEDA-3) criteria or its components.
Results: Patients with abnormal baseline sNfL had a higher risk of violating NEDA-3 (hazard ratio [HR] 2.28, 95% CI 1.27-4.09, = 0.006) and developing a new brain lesion (HR 2.47, 95% CI 1.30-4.69, = 0.006), but not for a new relapse (HR 2.21, 95% CI 0.97-5.03, p = 0.058). Patients with both abnormal sNfL and thin GCIP had an even higher risk for NEDA-3 violation (HR 3.61, 95% CI 1.77-7.36, = 4.2e), new brain lesion (HR 3.19, 95% CI 1.51-6.76, = 0.002), and new relapse (HR 5.38, 95% CI 1.61-17.98, = 0.006) than patients with abnormal sNfL alone.
Conclusions: In patients with early MS, the presence of both abnormal sNfL and thin GCIP is a stronger risk factor for future disease activity than the presence of each parameter alone.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362351 | PMC |
http://dx.doi.org/10.1212/NXI.0000000000001051 | DOI Listing |
J Neural Transm (Vienna)
January 2025
Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany.
Parkinson's disease (PD) is a chronic neurodegenerative disease of the elderly. Patients suffer from progressive motor and non-motor symptoms. Further, PD patients often present geriatric features like multimorbidity and polypharmacotherapy.
View Article and Find Full Text PDFTher Adv Neurol Disord
January 2025
Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
Background: Serum neurofilament light chain (sNfL) is a biomarker for neuro-axonal injury.
Objectives: To assess sNfL's utility as a diagnostic marker for Lyme neuroborreliosis (LNB).
Methods: We compared serum and CSF NfL levels in LNB patients and age-matched controls.
Mult Scler
January 2025
Blizard Institute, Barts and The London, London, UK.
Background: Biomarkers are needed to track progression in MS trials. Neurofilament heavy chain (NfH) has been underutilized due to assay limitations.
Objective: To investigate the added value of cerebrospinal fluid (CSF) NfH in secondary progressive multiple sclerosis (SPMS) using contemporary immunoassays.
J Neuroimmunol
January 2025
Institute of Clinical Chemistry, University Hospital Schleswig-Holstein Kiel/Lübeck, Germany.
Objectives: Herpes simplex virus 1 encephalitis (HSE) is the most common infectious encephalitis in developed countries. We aimed to evaluate the association of serum neurofilament light chain (sNfL) with disease severity, outcome and secondary anti-neuronal autoantibodies in a retrospective cohort study.
Methods: We retrospectively identified 30 patients with HSE and 132 controls (bacterial meningoencephalitis BM n = 27, non-bacterial meningitis NBM n = 33, healthy controls = 72).
Lupus Sci Med
January 2025
Institute of Rheumatology, Prague 2, Czech Republic
Background: The neurofilament light chain (NfL) in cerebrospinal fluid (CSF) and serum as a marker of neuronal damage may be a potential biomarker of neuropsychiatric involvement in SLE (NPSLE).
Methods: 80 patients with SLE were included.We obtained paired serum and CSF samples from 48 patients (NPSLE n=32, non-NPSLE n=16) and 31 controls.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!